Preclinical approaches to study the biology and treatment of brain metastases

Seminars in Cancer Biology

Volumn 21, Issue 2, 2011, Pages 123-130

  Cruz Munñoz, William ^a   Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

CNS; Experimental metastasis; Preclinical metastasis models; Spontaneous metastasis; Therapy

Indexed keywords

ALPHA INTERFERON; ANTIMETASTATIC AGENT; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CEDIRANIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GPI 16552; LAPATINIB; LIPOSOME; LOMUSTINE; MANNITOL; METHOTREXATE; NANOPARTICLE; SAGOPILONE; STAT3 PROTEIN; STAT4 PROTEIN; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT; WI 1066; WI 1193; WP 1066; WP 1193;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG EFFICACY; DRUG PENETRATION; HUMAN; INTRACRANIAL TUMOR; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS POTENTIAL; MICROMETASTASIS; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952072017     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.12.001     Document Type: Review

References (91)

1. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007, 13(6):1648-1655.
2. Bafaloukos D., Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004, 30(6):515-520.
3. Gore E., Choy H. Non-small cell lung cancer and central nervous system metastases: should we be using prophylactic cranial irradiation?. Semin Radiat Oncol 2004, 14(4):292-297.
4. Wong E.T., Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004, 9(1):68-79.
5. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75(1):5-14.
6. Soffietti R., Ruda R., Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008, 20(6):676-684.
7. Aragon-Ching J.B., Zujewski J.A. CNS metastasis: an old problem in a new guise. Clin Cancer Res 2007, 13(6):1644-1647.
8. Schackert G., Price J.E., Zhang R.D., Bucana C.D., Itoh K., Fidler I.J. Regional growth of different human melanomas as metastases in the brain of nude mice. Am J Pathol 1990, 136(1):95-102.
9. Palmieri D., Lockman P.R., Thomas F.C., Hua E., Herring J., Hargrave E., et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009, 15(19):6148-6157.
10. Cranmer L.D., Trevor K.T., Bandlamuri S., Hersh E.M. Rodent models of brain metastasis in melanoma. Melanoma Res 2005, 15(5):325-356.
11. Tarhini A.A., Agarwala S.S. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004, 16(2):161-166.
12. Ewend M.G., Williams J.A., Tabassi K., Tyler B.M., Babel K.M., Anderson R.C., et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996, 56(22):5217-5223.
13. Maher E.A., Mietz J., Arteaga C.L., DePinho R.A., Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Res 2009, 69(15):6015-6020.
14. Arslan C., Dizdar O., Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 2009, 11(7):1089-1100.
15. Mayer M. A patient perspective on brain metastases in breast cancer. Clin Cancer Res 2007, 13(6):1623-1624.
16. Khanna C., Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005, 26(3):513-523.
17. Schackert G., Fidler I.J. Development of in vivo models for studies of brain metastasis. Int J Cancer 1988, 41(4):589-594.
18. Zhang R.D., Fidler I.J., Price J.E. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991, 11(4):204-215.
19. Ishikawa M., Fernandez B., Kerbel R.S. Highly pigmented human melanoma variant which metastasizes widely in nude mice: including to skin and brain. Cancer Res 1988, 48(17):4897-4903.
20. Engebraaten O., Fodstad O. Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats. Int J Cancer 1999, 82(2):219-225.
21. Palmieri D., Chambers A.F., Felding-Habermann B., Huang S., Steeg P.S. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007, 13(6):1656-1662.
22. Weil R.J., Palmieri D.C., Bronder J.L., Stark A.M., Steeg P.S. Breast cancer metastasis to the central nervous system. Am J Pathol 2005, 167(4):913-920.
23. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008, 100(15):1092-1103.
24. Kong L.Y., Gelbard A., Wei J., Reina-Ortiz C., Wang Y., Yang E.C., et al. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 2010, 16(9):2550-2561.
25. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459(7249):1005-1009.
26. Yang J., Mani S.A., Weinberg R.A. Exploring a new twist on tumor metastasis. Cancer Res 2006, 66(9):4549-4552.
27. Hiroishi S., Morimoto J., Taniguchi Y., Mori H. Multiple metastases of mammary carcinoma cell lines isolated from feral mouse. Cancer Lett 1995, 92(1):83-86.
28. Fidler I.J., Schackert G., Zhang R.D., Radinsky R., Fujimaki T. The biology of melanoma brain metastasis. Cancer Metastasis Rev 1999, 18(3):387-400.
29. Talmadge J.E., Singh R.K., Fidler I.J., Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170(3):793-804.
30. Rolland Y., Demeule M., Fenart L., Béliveau R. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res 2009, 22(1):86-98.
31. Nguyen D.X., Chiang A.C., Zhang X.H., Kim J.Y., Kris M.G., Ladanyi M., et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138(1):51-62.
32. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006, 66(6):3188-3196.
33. Palmieri D., Bronder J.L., Herring J.M., Yoneda T., Weil R.J., Stark A.M., et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007, 67(9):4190-4198.
34. Menter D.G., Herrmann J.L., Marchetti D., Nicolson G.L. Involvement of neurotrophins and growth factors in brain metastasis formation. Invas Metast 1994, 14(1-6):372-384.
35. Krüger A., Sanchez-Sweatman O.H., Martin D.C., Fata J.E., Ho A.T., Orr F.W., et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998, 16(18):2419-2423.
36. Mendes O., Kim H.T., Lungu G., Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metast 2007, 24(5):341-351.
37. Rubio N., España L., Fernández Y., Blanco J., Sierra A. Metastatic behavior of human breast carcinomas overexpressing the Bcl-x(L) gene: a role in dormancy and organospecificity. Lab Invest 2001, 81(5):725-734.
38. Perides G., Zhuge Y., Lin T., Stins M.F., Bronson R.T., Wu J.K. The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis. BMC Cancer 2006, 6:56.
39. Yoshimasu T., Sakurai T., Oura S., Hirai I., Tanino H., Kokawa Y., et al. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 2004, 95(2):142-148.
40. Chen E.I., Hewel J., Krueger J.S., Tiraby C., Weber M.R., Kralli A., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007, 67(4):1472-1486.
41. Zhang C., Zhang F., Tsan R., Fidler I.J. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 2009, 69(3):828-835.
42. Tester A.M., Waltham M., Oh S.J., Bae S.N., Bills M.M., Walker E.C., et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 2004, 64(2):652-658.
43. Kim L.S., Huang S., Lu W., Lev D.C., Price J.E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metast 2004, 21(2):107-118.
44. Cruz-Munoz W, Kerbel RS. Metronomic chemotherapy for treatment of metastatic disease: from preclinical research to clinical trials. In: Lyden D, Welch DR, Psaila B, editors. Cancer metastasis: biologic basis and therapeutics; in press.
45. Yang M., Jiang P., Sun F.X., Hasegawa S., Baranov E., Chishima T., et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 1999, 59(4):781-786.
46. Yang M., Jiang P., An Z., Baranov E., Li L., Hasegawa S., et al. Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 1999, 5(11):3549-3559.
47. Howard R.B., Mullen J.B., Pagura M.E., Johnston M.R. Characterization of a highly metastatic: orthotopic lung cancer model in the nude rat. Clin Exp Metast 1999, 17(2):157-162.
48. Alterman A.L., Stackpole C.W. B16 melanoma spontaneous brain metastasis: occurrence and development within leptomeninges blood vessels. Clin Exp Metastasis 1989, 7(1):15-23.
49. Patel J.K., Didolkar M.S., Pickren J.W., Moore R.H. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978, 135(6):807-810.
50. Tao K., Fang M., Alroy J., Sahagian G.G. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008, 8:228.
51. Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 2008, 68(12):4500-4505.
52. Hicks D.G., Yoder B.J., Short S., Tarr S., Prescott N., Crowe J.P., et al. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 2006, 12(22):6702-6708.
53. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative: express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006, 30(9):1097-1104.
54. Stark A.M., Tongers K., Maass N., Mehdorn H.M., Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 2005, 131(3):191-198.
55. Sarris M., Scolyer R.A., Konopka M., Thompson J.F., Harper C.G., Lee C.S. Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Res 2004, 14(1):23-27.
56. Harabin-Słowińska M., Słowiński J., Konecki J., Mrówka R. Expression of adhesion molecule CD44 in metastatic brain tumors. Folia Neuropathol 1998, 36(3):179-184.
57. Bibby M.C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004, 40(6):852-857.
58. Deeken J.F., Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13(6):1663-1674.
59. Patel R.R., Mehta M.P. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 2007, 13(6):1675-1683.
60. Motl S., Zhuang Y., Waters C.M., Stewart C.F. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006, 45(9):871-903.
61. Schadendorf D., Hauschild A., Ugurel S., Thoelke A., Egberts F., Kreissig M., et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006, 17(10):1592-1597.
62. Stewart D.J. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994, 20(2):121-139.
63. Yang H. Nanoparticle-mediated brain-specific drug delivery: imaging, and diagnosis. Pharm Res 2010, 27(9):1759-1771.
64. Madhankumar A.B., Slagle-Webb B., Wang X., Yang Q.X., Antonetti D.A., Miller P.A., et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther 2009, 8(3):648-654.
65. Inoue T., Yamashita Y., Nishihara M., Sugiyama S., Sonoda Y., Kumabe T., et al. Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro Oncol 2009, 11(2):151-157.
66. Kinoshita M., McDannold N., Jolesz F.A., Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2006, 340(4):1085-1090.
67. Kinoshita M., McDannold N., Jolesz F.A., Hynynen K. Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 2006, 103(31):11719-11723.
68. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 2008, 60(10):1209-1217.
69. Joo K.M., Park K., Kong D.S., Song S.Y., Kim M.H., Lee G.S., et al. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor. Oncol Rep 2008, 19(1):17-23.
70. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhänel M., Spruss T., et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002, 110(9):1309-1318.
71. Breedveld P., Beijnen J.H., Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006, 27(1):17-24.
72. Barth R.F., Yang W., Bartus R.T., Rotaru J.H., Ferketich A.K., Moeschberger M.L., et al. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. Int J Radiat Oncol Biol Phys 2002, 52(3):858-868.
73. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003, 2(4 Suppl. 1):S134-S139.
74. Hoffmann J., Fichtner I., Lemm M., Lienau P., Hess-Stumpp H., Rotgeri A., et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009, 11(2):158-166.
75. Baschnagel A., Russo A., Burgan W.E., Carter D., Beam K., Palmieri D., et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8(6):1589-1595.
76. Thomas F.C., Taskar K., Rudraraju V., Goda S., Thorsheim H.R., Gaasch J.A., et al. Uptake of ANG1005: a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009, 26(11):2486-2494.
77. Ewend M.G., Sampath P., Williams J.A., Tyler B.M., Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 1998, 43(5):1185-1193.
78. Tentori L., Leonetti C., Scarsella M., Muzi A., Vergati M., Forini O., et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 2005, 41(18):2948-2957.
79. JuanYin J., Tracy K., Zhang L., Munasinghe J., Shapiro E., Koretsky A., et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis 2009, 26(5):403-414.
80. Deshmukh P., Glick R.P., Lichtor T., Moser R., Cohen E.P. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg 2001, 94(2):287-292.
81. Potmesil M., Vardeman D., Kozielski A.J., Mendoza J., Stehlin J.S., Giovanella B.C. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 1995, 55(23):5637-5641.
82. Grossi P.M., Ochiai H., Archer G.E., McLendon R.E., Zalutsky M.R., Friedman A.H., et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003, 9(15):5514-5520.
83. Hasegawa H., Shapiro W.R., Posner J.B. Chemotherapy of experimental metastatic brain tumors in female Wistar rats. Cancer Res 1979, 39(7 Pt 1):2691-2697.
84. Kominsky S.L., Tyler B., Sosnowski J., Brady K., Doucet M., Nell D. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 2007, 67(17):7977-7982.
85. Ausman J.I., Shapiro W.R., Rall D.P. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970, 30(9):2394-2400.
86. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
87. Tomasello G., de Azambuja E., Dinh P., Snoj N., Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008, 8(12):1883-1890.
88. Gluck S., Castrellon A. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. Am J Ther 2009, 16(6):585-590.
89. Metro G, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2010 (ahead of pub).
90. Sutherland S., et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer 2010, 102(6):995-1002.
91. Kong L.Y., Abou-Ghazal M.K., Wei J., Chakraborty A., Sun W., Qiao W., et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008, 14(18):5759-5768.